Context Capital Management LLC Purchases New Stake in Drugs Made In America Acquisition Corp. $DMAA

Context Capital Management LLC purchased a new stake in shares of Drugs Made In America Acquisition Corp. (NASDAQ:DMAA) in the 3rd quarter, Holdings Channel reports. The institutional investor purchased 250,000 shares of the company’s stock, valued at approximately $2,568,000.

A number of other large investors have also added to or reduced their stakes in DMAA. Karpus Management Inc. increased its position in shares of Drugs Made In America Acquisition by 18.1% in the second quarter. Karpus Management Inc. now owns 2,744,109 shares of the company’s stock valued at $27,990,000 after acquiring an additional 420,075 shares during the period. Wolverine Asset Management LLC grew its stake in shares of Drugs Made In America Acquisition by 22.2% in the third quarter. Wolverine Asset Management LLC now owns 1,249,128 shares of the company’s stock worth $12,829,000 after purchasing an additional 227,222 shares during the last quarter. Boothbay Fund Management LLC bought a new stake in shares of Drugs Made In America Acquisition in the second quarter worth about $5,814,000. Radcliffe Capital Management L.P. purchased a new position in Drugs Made In America Acquisition during the 2nd quarter valued at about $1,293,000. Finally, Clear Street LLC bought a new position in Drugs Made In America Acquisition during the 2nd quarter valued at approximately $1,149,000.

Drugs Made In America Acquisition Price Performance

Drugs Made In America Acquisition stock opened at $10.46 on Wednesday. Drugs Made In America Acquisition Corp. has a fifty-two week low of $9.96 and a fifty-two week high of $10.48. The stock’s 50 day simple moving average is $10.42 and its two-hundred day simple moving average is $10.34.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Drugs Made In America Acquisition in a research report on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Drugs Made In America Acquisition currently has a consensus rating of “Sell”.

Drugs Made In America Acquisition Company Profile

Drugs Made In America Acquisition Corp (NASDAQ: DMAA) is a special purpose acquisition company incorporated in Delaware with the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company’s stated focus is on identifying and acquiring one or more operating businesses in the U.S. pharmaceutical sector, particularly those involved in the domestic manufacturing of approved drugs, active pharmaceutical ingredients or related contract development and manufacturing services.

Operating as a blank‐check vehicle, Drugs Made In America Acquisition holds its funds in a trust account pending the completion of an initial business combination.